Autolus Therapeutics Ltd (AUTL)vsModerna Inc (MRNA)
AUTL
Autolus Therapeutics Ltd
$1.63
+5.16%
HEALTHCARE · Cap: $423.20M
MRNA
Moderna Inc
$214.17
+2.98%
HEALTHCARE · Cap: $87.04B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 1798% more annual revenue ($2.23B vs $117.39M). MRNA leads profitability with a -141.4% profit margin vs -238.6%. AUTL earns a higher WallStSmart Score of 32/100 (F).
AUTL
Avoid32
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AUTL.
Margin of Safety
+69.9%
Fair Value
$134.71
Current Price
$214.16
$79.45 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 118.4% year-over-year
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Weak financial health signals
Trading at 12.6x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AUTL
The strongest argument for AUTL centers on Revenue Growth. Revenue growth of 118.4% demonstrates continued momentum.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : AUTL
The primary concerns for AUTL are EPS Growth, Market Cap, Debt/Equity.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
AUTL profiles as a hypergrowth stock while MRNA is a turnaround play — different risk/reward profiles.
AUTL carries more volatility with a beta of 2.14 — expect wider price swings.
AUTL is growing revenue faster at 118.4% — sustainability is the question.
AUTL generates stronger free cash flow (-26M), providing more financial flexibility.
Bottom Line
AUTL scores higher overall (32/100 vs 21/100) and 118.4% revenue growth. MRNA offers better value entry with a 69.9% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Autolus Therapeutics Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T-cell therapies for the treatment of cancer. The company is headquartered in London, the United Kingdom.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?